Table 3 Administration of abobotulinumtoxinA at baseline (Visit 1) by country and overall

 Mean ± SD

563 ± 245

571 ± 159

647 ± 270

674 ± 219

503 ± 163

564 ± 235

 Median [range]

500 [50–1700]

500 [200–1000]

500 [120–1600]

500 [250–1000]

500 [150–1150]

500 [100–1502]

 Number of muscles injected; median [range]

3 [1–11]

3 [1–6]

4 [1–10]

4 [2–9]

3 [1–6]

5 [1–18]

 Splenius capitis

1087 (90.4)

113 (95.8)

87 (91.6)

95 (99.0)

52 (88.1)

249 (89.9)

 Sternocleidomastoid

967 (80.4)

102 (86.4)

83 (87.4)

95 (99.0)

44 (74.6)

196 (70.8)

 Trapezius

739 (61.5)

54 (45.8)

44 (46.3)

82 (85.4)

32 (54.2)

155 (56.0)

 Levator scapulae

569 (47.3)

39 (33.1)

55 (57.9)

52 (54.2)

28 (47.5)

174 (62.8)

 Semispinalis capitis

334 (27.8)

24 (20.3)

36 (37.9)

23 (24.0)

11 (18.6)

126 (45.5)

 Scalene group**

164 (13.8)

4 (3.4)

14 (14.7)

9 (9.4)

0

53 (19.1)

 Longissimus group**

86 (7.2)

4 (3.4)

4 (4.2)

0

0

57 (20.6)

 Splenius cervicis

60 (5.0)

1 (0.8)

3 (3.2)

0

0

44 (15.9)

 Obliquus capitis inferior

42 (3.5)

1 (0.8)

7 (7.4)

1 (1.0)

0

19 (6.9)

 Platysma

24 (2.0)

1 (0.8)

5 (5.3)

5 (5.2)

2 (3.4)

0

Number of injection points; median [range]

7.0 [1–34]

4.5 [1–16]

8.0 [2–27]

9.5 [4–28]

4.0 [1–6]

9.0 [1–34]

Injected volume (mL); median [range]

2.00 [0.2–12.0]

1.25 [0.6–5.0]

2.50 [0.6–8.0]

2.00 [0.5–5.0]

2.25 [0.7–4.6]

2.00 [0.2–12.0]

Use of injection guidance; n (%)

486 (40.5)

50 (42.4)

68 (71.6)

12 (12.5)

1 (1.7)

166 (59.9)

Interval since last injection (days);***

n/N = 385/849

n/N = 47/91

n/N = 20/62

n/N = 31/76

n/N = 19/54

n/N = 78/114

Median [range]

108.3 [15.0–317.7]

108.9 [68.8–284.2]

99.5 [57.7–214.0]

112.5 [76.9–256.5]

104.2 [50.8–198.0]

94.3 [15.0–225.0]